ADMA Biologics Inc

Good afternoon and welcome to the ADMA Biologics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call on Thursday, March 23rd, 2023. At this time, our participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce Skyla Bloom, Senior Director, Business Development and Corporate Strategy at ADMA Biologics.

Please go ahead.

Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics financial results for the fourth quarter and full year 2022 and recent corporate updates. I'm joined today by Adam Grossman, President and Chief Executive Officer and Brian Lenz, Executive Vice President, Chief Financial Officer, and General Manager of Atma Biocenters. During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and then Brian will provide an overview of the company's fourth quarter 2022 financial results. Finally, Adam will then provide some brief summary remarks before opening the call up for your questions. Earlier today, we issued a press release detailing the fourth quarter and full year 2022 financial results, and summarize certain achievements in recent corporate updates. The release is available on our website at www.admobiologics.com. Before we begin our formal comments, I'll remind you that we will be making forward-looking assertions during today's call that represent the company's intentions, expectations, or beliefs concerning future events, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks, and uncertainties, such as those detailed in today's press release announcing this call and in our filings with the SEC, which may cause actual results to differ materially from the results expressed or implied by such statements. In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update any such statements, except as required by the federal securities laws. We refer you to the disclosures notice section and our earnings release we issued today in the risk factors section of our 2022 annual report on form 10 K for the year ended December 31st, 2022 for a discussion of important factors that could cause actual results to differ materially from these forward looking statements. With that, I would like to now turn the call over to Adam Grossman. Adam.